Life Sciences

Tectrol and CUI Global

FOCUS Investment Banking Represents Tectrol in Business Sale

Sell Side M&A Investment Banking

Washington, DC (March 13, 2015) – FOCUS Investment Banking, a national middle market investment banking firm providing merger, acquisition, divestiture and corporate finance services announced today that Tectrol, Inc. has been acquired by CUI Global, Inc. (NASDAQ:CUI).  FOCUS represented Tectrol in the transaction.
Medvance and NAMSA

FOCUS Investment Banking Represents Medvance Ltd. in Acquisition by NAMSA FOCUS closes another international deal in the healthcare industry

Washington, DC (January 7, 2014) FOCUS, a national middle market investment banking firm providing merger, acquisition, divestiture and corporate finance services, announced that its client, Medvance Ltd., has been acquired by NAMSA. FOCUS represented Medvance in the transaction, adding another international deal to its list of completed 2013 transactions.
Pleiad and CROM Source

Middle Market Investment Banking Firm, FOCUS LLC, Represents Pleiad in Acquisition by CROMSOURCE International Transaction in Life Sciences and Clinical Research Organization Industry

Washington, DC (June 4, 2012) – FOCUS LLC, a national middle market investment banking firm providing merger, acquisition, divestiture and corporate finance services, announced that Pleiad, domiciled in Stirling,Scotland, with a substantial presence in the U.S. (Cambridge, Massachusetts) has been acquired by CROMSOURCE, headquartered in Verona, Italy. FOCUS represented Pleiad in the transaction.
Bioline and Meridian Bioscience

Middle Market Investment Banking Firm FOCUS LLC Represents the Bioline Group of Companies in its Sale to Meridian Bioscience, Inc. Deal Marks Tenth Deal for FOCUS in 2010

Washington DC (July 23, 2010) – FOCUS LLC, a national middle market investment banking firm providing merger, acquisition, divestiture and corporate finance services, announced today that the Bioline group of companies has been acquired by Meridian Bioscience, Inc. (NASDAQ: VIVO). FOCUS represented Bioline in this transaction.